Infectious disease test kit BCID2

for identification analysisfor blood diseasesblood culture

The BioFire BCID2 Panel tests for 43 targets associated with bloodstream infections, including gram-negative bacteria, gram-positive bacteria, yeast, and 10 antimicrobial resistance genes—all with one test and with results available in about an hour from positive blood culture. The BioFire BCID2 Panel features broadened inclusivity for Enterobacterales, new assays for fungal and anaerobic pathogens, and additional identification of coagulase-negative Staphylococcus species. The BioFire BCID2 Panel menu includes seven additional resistance genes, including carbapenemases and colistin resistance genes. An MREJ assay allows for more specific MRSA identification. Enhanced Antimicrobial Stewardship The IDSA recommends the addition of rapid diagnostic testing to an effective Antimicrobial Stewardship Program.3 A study at the Mayo Clinic shows that pairing the BioFire® FilmArray® Blood Culture Identification (BCID) Panel with antimicrobial stewardship provides the greatest benefit.4 Shorten Time to Optimal Therapy The BioFire BCID Panel and antimicrobial stewardship interventions decreased time to optimal therapy by 33.5 hours.1 Reduce Hospital Costs Faster organism identification and reduced time to optimal therapy can also lead to better economic outcomes. BioFire BCID Panel identification of coagulase-negative staphylococci contaminants resulted in shorter post-culture length of stay and saved roughly $30,000 per 100 patients tested.5